HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Clinical trials for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) trials appear
Sign up with your email to follow new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to stop nosebleeds in rare blood vessel disorder
Disease control Recruiting nowThis study tests an experimental drug called ATV-1601 in people with moderate to severe HHT, a condition that causes frequent nosebleeds and anemia. The trial has two parts: first, participants receive either the drug or a placebo to check safety and effectiveness; then, all elig…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Phase: PHASE1, PHASE2 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New ointment could tame HHT nosebleeds
Symptom relief Recruiting nowThis early-phase trial tests a new nasal ointment called TOR-582, which contains sirolimus, in 27 adults with hereditary hemorrhagic telangiectasia (HHT) who have frequent nosebleeds. Participants apply the ointment inside their nostrils twice daily for 12 weeks, with different s…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Phase: PHASE1 • Sponsor: Columbia University • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC